Undisclosed c-MET degrading EpiTAC / EpiBiologics - LARVOL DELTA

Discovery of c-MET degrading bispecific antibodies (EpiTACs) for NSCLC and other c-MET driven tumors (AACR 2025) - "These newly discovered degraders are being paired with novel c-MET binders that lack dimerization-induced signaling capacity, to create safer and more efficacious c-MET degrading therapeutics. In conclusion, eTPD represents a promising new drug modality, and EpiTACs have expanded the toolbox of extracellular targeted protein degraders to address challenging drug targets with a new approach."

Brain Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • EGFR • MET